DRG2: A Drug Target / Disease Biomarker (G1819)

Target Name: DRG2

NCBI ID: G1819

DRG2: A Drug Target / Disease Biomarker

DRG2 (doublecortin) is a protein that is expressed in the brain and is known for its role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease. It is a potential drug target (or biomarker) for the treatment of these diseases, and research is ongoing to determine its effectiveness.

DRG2 is a transmembrane protein that is expressed in the brain and is involved in the regulation of pain, anxiety, and other neurological processes. It is a member of the superfamily of cysteine-rich proteins, known as the cysteine-rich region (CRR) proteins, and is characterized by the presence of a unique cysteine residue that is able to form a disulfide bond with other cysteine residues. This unique property allows DRG2 to interact with a wide variety of molecules, including small molecules, peptides, and proteins, and makes it a promising target for drug development.

One of the key challenges in the development of DRG2 as a drug target is its high expression level in the brain, which can make it difficult to effectively target it without introducing unintended side effects. However, researchers are ongoing efforts to identify ways to target DRG2 without causing significant off-target effects.

In addition to its potential as a drug target, DRG2 has also been identified as a potential biomarker for neurodegenerative diseases. The ability of DRG2 to form a disulfide bond with other cysteine residues makes it a strong candidate for use as a protein biomarker, as it is expected to be highly stable and resistant to degradation.

Research is also underway to determine the effectiveness of DRG2 as a drug target for the treatment of neurodegenerative diseases. Preclinical studies have shown that DRG2 can be effectively targeted with small molecules and antibodies, and that it has the potential to significantly improve the treatment of these diseases.

Overall, DRG2 is a promising protein that has the potential to be a drug target (or biomarker) for the treatment of neurodegenerative diseases. Further research is needed to determine its effectiveness and to develop safe and effective treatments for the treatment of these diseases.

Protein Name: Developmentally Regulated GTP Binding Protein 2

Functions: Catalyzes the conversion of GTP to GDP through hydrolysis of the gamma-phosphate bond in GTP. When hydroxylated at C-3 of 'Lys-21' by JMJD7, may bind to RNA and play a role in translation

More Common Targets